36 results about "Activated coagulation factor" patented technology

The present invention relates to a platelet aggregation function detection kit, and a method using the kit to detect platelet aggregation function. The detection kit mainly includes the following detection reagents: a sodium citrate whole blood activator, a fibrin activator and a platelet activator. The fibrin activator comprises: recombinant batroxobin and activated clotting factor. By using the kit of the invention to detect, blood sample processing requirements are low, repeat testing variability is small, accuracy and stability are high, use and storage are convenient, detection cost is low, and promotion is easy.

The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.

The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula:

wherein R¹ is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.;

Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

The invention discloses a method for detecting an activated blood coagulation factor XI in human intravenous immunoglobulin. The method comprises the steps as follows: (1) mixing an IVIG (intravenous immunoglobulin) sample with specially-preprocessed platelet-poor plasma (PPP); (2) adding a thrombin specific fluorogenic substrate with a phospholipid agent into a reaction system; (3) adding an initiation factor for starting a TGT (thrombin generation test), wherein the initiation factor comprises a calcium ion source and the phospholipid agent; (4) obtaining a thrombin generation curve providing parameters by the optimized reaction system; and (5) negatively correlating the peak time of thrombin (TTP) of the detected sample with the FXIa (activated blood coagulation factor XI) level in the sample. The FXIa level in the detected sample can be indirectly obtained by comparing the TTP of the detected sample with that of an FXIa standard sample. The method is suitable for detecting residual micro FXIa in human intravenous immunoglobulin (IVIG) products and is used for extracorporal evaluation of thrombosis risk of related products.

Formulations for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient; and formulations for neutralizing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.

The invention provides edoxaban tosilate hydrate. Edoxaban is a micromolecule oral anticoagulant drug, and is a blood coagulation factor X(FXa) retarding agent. In the process of blood coagulation, the activated coagulation factor X(FXa) activates prothrombin (FII) into thrombin (FIIa), formation of fibrin is promoted, and thrombus is formed, so that FXa is developed as a main target of a new generation anticoagulant drug. Edoxaban is the oral anticoagulant drug by selectively, reversibly and directly inhibiting FXa in order to inhibit formation of thrombus.

The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis.

The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis.

The invention discloses a pharmaceutical composition of hemocoagulase. The pharmaceutical composition is characterized in that the pharmaceutical composition is prepared from 0.00005 to 0.0005 percentof a hemocoagulase composition and the balance of a pharmaceutically acceptable carrier. The composition is applied to preparation of a medicine for treating Haemophilia B (coagulation factor IX deficiency). Active components in the hemocoagulase comprise hemocoagulase, i.e., a thrombin-like enzyme (batroxobin), and a phospholipid dependent coagulation factor X activating agent (FXA). A bleedingstopping process of the hemocoagulase does not depend on a coagulation factor IX and is mainly used for fibrin and an activated coagulation factor X, and has the effect of treating bleeding of the haemophilia B. After the hemocoagulase is used for treating, platelet aggregation can be remarkably enhanced, and the formation of blood clots or fibrin clots in a patient with the haemophilia B is recovered.

The invention provides the application of heparin sodium to the preparation of an external drug for treating haemorrhoids. The heparin sodium is acid mucopolysaccharide-heparin (The molecular weight is 4000-15000), can interfere with many links in the hemagglutination process and has an anti-coagulation effect both in vivo and in vitro; in combination with antithrombin III (AT-III), the heparin sodium mainly enhances an inhibitory effect of the latter on activated coagulation factors II, IX, X, XI and XII and has the effects of preventing platelet aggregation and damage, hindering the formation of thromboplastin, preventing prothrombin from becoming thrombin and inhibiting thrombin, thereby preventing fibrinogen from becoming fibrinogen and playing an anti-coagulation role. The invention utilizes heparin for dermatology (heparin sodium cream) to treat internal and external hemorrhoids, mixed hemorrhoids and acute thrombotic hemorrhoid and applies the anticoagulation, blood stasis and thrombolysis effects of the heparin sodium to relieve swelling and pain; a blood vessel is dredged, retracted and restored, so that the haemorrhoids is treated. The heparin sodium is applied to an anus(Pay attention to discontinuation when bleeding occurs) and is safe, convenient and effective.

Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs:

wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.

The invention relates to an immobilized snake venom blood coagulation factor activator and a preparation method of an activated blood coagulation factor. The immobilized snake venom blood coagulationfactor activator comprises an active component and a vector provided with the active component immobilizedly, wherein the active component is a snake venom extract. The preparation method of the activated blood coagulation factor comprises the steps that pig plasma or cow plasma is made through a filtering column filled with the immobilized snake venom blood coagulation factor activator to obtainthe activated blood coagulation factor by collecting effluent or the immobilized snake venom blood coagulation factor activator is added into the pig plasma or the cow plasma for stirring for 1-5 hours to obtain the activated blood coagulation factor through filtering. The immobilized snake venom blood coagulation factor activator can be used repeatedly, and when the primarily-extracted blood coagulation factor is activated, only the immobilized snake venom blood coagulation factor activator needs to be removed, so that the snake venom component in extraction liquid is removed at the same time; moreover, by means of the method, activation reaction time is shortened, the factor specific activity after activation is improved, and the activation specificity is high.

The present invention relates to a 5-amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative represented by the general formula:

wherein R¹ is a hydrogen atom or a lower alkyl group;

• R² represents a hydrogen atom, an optionally substituted lower alkyl group, etc.;
• R³ is a di(lower alkyl)amino group, a lower alkyl group, a cycloalkyl group, etc.;
• Q is a hydrogen atom or an optionally substituted lower alkyl group; and
• Z is a hydrogen atom or a hydroxy group, etc.,

or a pharmaceutically acceptable salt thereof, which exerts a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same, a pharmaceutical use thereof and an intermediate thereof.

The invention relates to the technical field of biological products, in particular to a method for rapidly extracting human immunoglobulin from blood plasma. According to the invention, plasma is usedas a raw material, octanoic acid with a specific concentration is adopted for direct precipitation, the component reaction steps are reduced, and the final product is good in quality and high in yield and basically does not contain activated blood coagulation factor XI and other impurities, which can effectively avoid the thrombogenic risk in the process of product use, and reduce the athromboticadverse reaction of the product. The production method is simple, the process period is short, component reaction steps in a plasma low-temperature ethanol process are not needed, the immunoglobulincan be rapidly prepared, the method is particularly suitable for preparing specific immunoglobulin for sudden large-scale epidemic infection, and the specific immune antibody preparation with high efficiency and high safety can be quickly provided for patients.

The invention discloses an anti-activation coagulation factor V monoclonal antibody. The anti-activation coagulation factor V monoclonal antibody has a light chain amino acid sequence shown in the formula of SEQ ID NO: 3 and a heavy chain amino acid sequence shown in the formula of SEQ ID NO: 4. The invention discloses a preparation method and use of the monoclonal monomer. The anti-activation coagulation factor V monoclonal antibody has strong binding ability to an activated coagulation factor V and can be used for detection of the activated coagulation factor V.

The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.